SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: D.Lu who wrote (811)3/22/2006 11:14:36 AM
From: tuck   of 946
 
I'll let kenhott speak for himself, but I feel Bianco is being a little wild in suggesting the CPOP regimen should be studied in first line settings, based on these results. Unless Pix is going to be less expensive than dox, which it had better not be. I don't see insurers going for it unless it could handily beat standard of care, which, as the PR admits, has a pretty good track record. That said, it would expand the market for Pix if it could go into first line settings, but CTIC doesn't have the money to fund the trial, given its XYOTAX gamble.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News